BDXB Stock Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Becton Dickinson Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$54.69|
|52 Week High||US$60.00|
|52 Week Low||US$50.21|
|1 Month Change||4.23%|
|3 Month Change||2.82%|
|1 Year Change||-3.32%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||8.30%|
Recent News & Updates
|BDXB||US Medical Equipment||US Market|
Return vs Industry: BDXB underperformed the US Medical Equipment industry which returned -0.4% over the past year.
Return vs Market: BDXB underperformed the US Market which returned 7.7% over the past year.
|BDXB Average Weekly Movement||2.5%|
|Medical Equipment Industry Average Movement||8.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: BDXB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BDXB's weekly volatility (3%) has been stable over the past year.
About the Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
Becton Dickinson Fundamentals Summary
|BDXB fundamental statistics|
Is BDXB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BDXB income statement (TTM)|
|Cost of Revenue||US$10.67b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 03, 2022
|Earnings per share (EPS)||7.02|
|Net Profit Margin||9.89%|
How did BDXB perform over the long term?See historical performance and comparison
1.3%Current Dividend Yield
Does BDXB pay a reliable dividends?See BDXB dividend history and benchmarks
|Becton Dickinson dividend dates|
|Ex Dividend Date||Feb 14 2022|
|Dividend Pay Date||Mar 01 2022|
|Days until Ex dividend||24 days|
|Days until Dividend pay date||39 days|
Does BDXB pay a reliable dividends?See BDXB dividend history and benchmarks
Is Becton Dickinson undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BDXB ($54.69) is trading below our estimate of fair value ($81.82)
Significantly Below Fair Value: BDXB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BDXB is good value based on its PE Ratio (37.6x) compared to the US Medical Equipment industry average (46.1x).
PE vs Market: BDXB is poor value based on its PE Ratio (37.6x) compared to the US market (16.9x).
Price to Earnings Growth Ratio
PEG Ratio: BDXB is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: BDXB is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (3.5x).
How is Becton Dickinson forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDXB's forecast earnings growth (14.1% per year) is above the savings rate (2%).
Earnings vs Market: BDXB's earnings (14.1% per year) are forecast to grow faster than the US market (13.1% per year).
High Growth Earnings: BDXB's earnings are forecast to grow, but not significantly.
Revenue vs Market: BDXB's revenue (3.2% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: BDXB's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDXB's Return on Equity is forecast to be low in 3 years time (15%).
How has Becton Dickinson performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDXB has a large one-off loss of $693.0M impacting its September 30 2021 financial results.
Growing Profit Margin: BDXB's current net profit margins (9.9%) are higher than last year (4.5%).
Past Earnings Growth Analysis
Earnings Trend: BDXB's earnings have grown by 16.1% per year over the past 5 years.
Accelerating Growth: BDXB's earnings growth over the past year (161%) exceeds its 5-year average (16.1% per year).
Earnings vs Industry: BDXB earnings growth over the past year (161%) exceeded the Medical Equipment industry 51.2%.
Return on Equity
High ROE: BDXB's Return on Equity (8.8%) is considered low.
How is Becton Dickinson's financial position?
Financial Position Analysis
Short Term Liabilities: BDXB's short term assets ($8.8B) exceed its short term liabilities ($6.6B).
Long Term Liabilities: BDXB's short term assets ($8.8B) do not cover its long term liabilities ($23.6B).
Debt to Equity History and Analysis
Debt Level: BDXB's net debt to equity ratio (64.7%) is considered high.
Reducing Debt: BDXB's debt to equity ratio has reduced from 151.5% to 74.4% over the past 5 years.
Debt Coverage: BDXB's debt is well covered by operating cash flow (26.4%).
Interest Coverage: BDXB's interest payments on its debt are well covered by EBIT (7.3x coverage).
What is Becton Dickinson current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: BDXB's dividend (1.32%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.34%).
High Dividend: BDXB's dividend (1.32%) is low compared to the top 25% of dividend payers in the US market (3.49%).
Stability and Growth of Payments
Stable Dividend: BDXB's dividends per share have been stable in the past 10 years.
Growing Dividend: BDXB's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48%), BDXB's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BDXB's dividends in 3 years are forecast to be well covered by earnings (29.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Polen (48 yo)
Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD14.19M) is about average for companies of similar size in the US market ($USD11.31M).
Compensation vs Earnings: Tom's compensation has increased by more than 20% in the past year.
Experienced Management: BDXB's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: BDXB's board of directors are considered experienced (8.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Becton, Dickinson and Company's employee growth, exchange listings and data sources
- Name: Becton, Dickinson and Company
- Ticker: BDXB
- Exchange: NYSE
- Founded: 1897
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$75.243b
- Shares outstanding: 285.04m
- Website: https://www.bd.com
Number of Employees
- Becton, Dickinson and Company
- 1 Becton Drive
- Franklin Lakes
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/20 23:51|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.